Jul 11, 2026Journal ArticleCorrelates of Dolutegravir Resistance in Low- and Middle-Income Countries: A Combined Analysis of Drug Resistance Surveys in Four Countries.Written by 1 Roon author & 13 others Via Clinical Infectious Diseases
ResearchVirology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites
ResearchEmergence of Acquired HIV Drug Resistance Among Individuals Receiving Dolutegravir-Based Antiretroviral Therapy in Uganda: A National Laboratory-Based Survey 2023
ResearchThe promise of a "cure" for HIV: implications for the future of PEPFAR-supported HIV programmes
ResearchHigh viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020-July 2021
ResearchHIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique
ResearchBeyond the 95s: What happens when uniform program targets are applied across a heterogenous HIV epidemic in Eastern and Southern Africa?
ResearchPredicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study
ResearchHIV-1 drug resistance mutations among individuals with low-level viraemia while taking combination ART in Botswana